Phase 2 N=37 Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 16 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=2,305 Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
Heart Disease · Stroke · Ischemic Heart Disease
Primary: Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death — 7.93; 7.47 events per 100 patient-years — p=0.40
Phase 2 N=66 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Rectal Cancer · Cancer of the Rectum · Colorectal Cancer
Primary: Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment…
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 2 N=20 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Pleural Mesothelioma · Peritoneal Mesothelioma
Primary: Clinical Response Rate (PR+CR) — 0; 0 Participants
N/A N=62 Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips
Lip Augmentation
Primary: Subject Rating of the Natural Look and Feel of the Lips — 52.5; 35.6; 11.9; 0 Percentage of subjects
Phase 2 N=45 Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Recurrent Ovarian Epithelial Cancer · Recurrent Primary Peritoneal Cavity Cancer · Stage IIIA Ovarian Epithelial Cancer
Primary: Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR) — 2.5; 0; 15; 40 Percentage of Participants
Phase 2 N=45 Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
Pancreatic Cancer
Primary: Rate of Participants Achieving Complete Response or Partial Response to Therapy. — 6; 25; 0 participants
Phase 4 N=200 Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Staphylococcal Infection · Abscess · Staphylococcal Skin Infection
Primary: Clinical Improvement at the 48-72 Hour Clinical Follow-up — 94; 97 participants
Phase 2 N=57 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-free Survival — .438; .292 proportion of participants
Phase 3 N=260 Nepafenac Compared to Placebo for Ocular Pain and Inflammation
Cataract
Primary: Proportion of Subjects With Clinical Cure at Day 14 — 80.3; 39.3 Percentage of subjects — p=<0.0001
Phase 3 N=660 Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean IOP at Month 3 for Each Assessment Timepoint (8 AM, + 2 h, + 7 h, and + 9 h) — 20.5; 21.6; 23.3; 17.2 millimeters mercury (mm Hg)
Phase 1 N=14 Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Hematologic Malignancy · Malignant Lymphoma
Primary: Area Under the Plasma Concentration Time-curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t)of Romidepsin — 2225.1; 3966.3 ng*hr/mL
Phase 2 N=26 Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
Recurrent Cervical Cancer · Recurrent Vaginal Cancer · Stage IB Cervical Cancer
Primary: Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and…
Phase 2 N=157 A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
Renal Failure , Chronic · Anemia
Primary: Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks) — 0.3; 0.9 g/dL — p=.0062